-
Basel, December 8, 2022 — Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with PNH met its primary endpoint1. Topline results showed a significant proportion of patients treated with iptacopan (200 mg twice daily…Reimagine MedicineMedical InnovationsInnovation
-
Basel, December 13, 2022 — Novartis today announced detailed results from the pivotal Phase III APPLY-PNH trial1. The results showed a vast majority of patients with paroxysmal nocturnal hemoglobinuria (PNH) who received the investigational oral monotherapy iptacopan achieved clinically meaningful increases in hemoglobin levels compared to anti-C5…Reimagine MedicineMedical InnovationsInnovation
-
Ad-hoc-Mitteilung gemäss Art. 53 KRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Annonce événementielle au sens de l’art. 53 RCExercice entierReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Basel, February 4, 2023 – Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating Cosentyx® (secukinumab) in moderate-to-severe hidradenitis suppurativa (HS)1. In two of the largest Phase III trials conducted in HS, Cosentyx treatment response rates continued to improve beyond…Reimagine MedicineInnovation
-
Annonce événementielle au sens de l’art. 53 RC
Reimagine MedicineMedical InnovationsInnovationAd Hoc -
Annonce événementielle au sens de l’art. 53 RC
Reimagine MedicineMedical InnovationsInnovationAd Hoc -
Ad-hoc-Mitteilung gemäss Art. 53 KR
Reimagine MedicineMedical InnovationsInnovationAd Hoc -
Ad-hoc-Mitteilung gemäss Art. 53 KR
Reimagine MedicineMedical InnovationsInnovationAd Hoc -
Basel, November 7, 2022 — Novartis today announced results from the Phase II open-label extension ORION-3 trial, which showed that Leqvio provides effective low-density lipoprotein cholesterol (LDL-C) reduction over a four-year period in patients with either atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalent, and elevated LDL-…Reimagine MedicineMedical InnovationsInnovation
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineMedical InnovationsInnovationAd Hoc